Federal Register / Vol. 75, No. 248 / Tuesday, December 28, 2010 / Notices 81625 

training programs, identify resources 

that will address the gaps and further 

strengthen the outcomes from these 

efforts, examine testimony from the 

experts in the field, and offer 

recommendations for improvement of 

these training programs to the Secretary 

and the Congress. 

Agenda: The ACICBL agenda includes 

an overview of the Committee’s general 

business activities, an orientation for the 

eight newly appointed members, 

presentations by and dialogue with 

experts, and discussion sessions specific 

to the development of recommendations 

to be addressed in the 11th Annual 

ACICBL Report. Agenda items are 

subject to change as dictated by the 

priorities of the Committee. 

SUPPLEMENTARY INFORMATION: Requests 

to make oral comments or to provide 

written comments to the ACICBL should 

be sent to Dr. Joan Weiss, Designated 

Federal Official at the contact 

information below. Individuals who 

plan to attend the meeting and need 

special assistance should notify Dr. 

Weiss at least 10 days prior to the 

meeting, using the address and phone 

number below. Members of the public 

will have the opportunity to provide 

comments at the meeting. 

FOR FURTHER INFORMATION CONTACT: 

Anyone requesting additional details 

should contact Dr. Joan Weiss, 

Designated Federal Official within the 

Bureau of Health Professions, Health 

Resources and Services Administration. 

Dr. Weiss may be reached by one of the 

three following methods: (1) Via written 

request to: Dr. Joan Weiss, Designated 

Federal Official, Bureau of Health 

Professions, Health Resources and 

Services Administration, Parklawn 

Building, Room 9–36, 5600 Fishers 

Lane, Rockville, Maryland 20857; (2) via 

telephone at (301) 443–6950; or (3) via 

e-mail at jweiss@hrsa.gov. In the 

absence of Dr. Weiss, CAPT Norma J. 

Hatot, Senior Nurse Consultant, may be 

contacted via telephone at (301) 443– 

2681 or by e-mail at nhatot@hrsa.gov. 

Dated: December 21, 2010. 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–32560 Filed 12–27–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Hesperetin Therapy for Metabolic 

Syndrome and Insulin Resistance 

Description of Technology: 

Hesperidin is a flavonoid compound 

found in citrus fruits. Large 

epidemiological studies have linked 

increased consumption of flavonoidrich foods, such as citrus, with reduced 

cardiovascular morbidity and mortality. 

Investigators from the National Center 

for Complementary and Alternative 

Medicine have demonstrated that 

administration of oral hesperidin to 

patients with metabolic syndrome 

attenuates biomarkers of inflammation 

and improves blood vessel relaxation, 

lipid cholesterol profiles, and insulin 

sensitivity when compared to controls. 

Thus, hesperidin and its active aglycone 

form, hesperetin, may be effective 

agents for the treatment of diabetes, 

obesity, metabolic syndrome, 

dyslipidemias, and their cardiovascular 

complications including hypertension, 

atherosclerosis, coronary heart disease, 

and stroke. This technology discloses 

methods for using a hesperetin 

composition to treat metabolic 

syndrome and insulin resistance. 

Applications: Therapeutics for 

metabolic syndrome and insulin 

resistance. 

Development Status: Clinical trial 

data available. 

Inventors: Michael J. Quon and 

Ranganath Muniyappa (NCCAM). 

Publications: Manuscript in 

preparation. 

Patent Status: U.S. Provisional 

Application No. 61/369,229 filled 30 

July 2010 (HHS Reference No. E–148– 

2010/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Tara L. Kirby, 

Ph.D.; 301–435–4426; 

kirbyt@mail.nih.gov. 

Substituted Triazine and Purine 

Compounds for the Treatment of 

Chagas Disease and African 

Trypanosomiasis 

Description of Technology: Parasitic 

protozoa are responsible for a wide 

variety of infections in both humans and 

animals. Trypanosomiasis poses health 

risks to millions of people across 

multiple countries in Africa and North 

and South America. Visitors to these 

regions, such as business travelers and 

tourists, are also at risk for contracting 

parasitic diseases. There are two types 

of African trypanosomiasis, also known 

as sleeping sickness. One type is caused 

by the parasite Trypanosoma brucei 

gambiense, and the other is caused by 

the parasite Trypanosoma brucei 

rhodesiensi. If left untreated, African 

sleeping sickness results in death. 

Chagas disease, caused by Trypanosoma 

cruzi (T. cruzi), affects millions of 

people in Mexico and South and Central 

America. Untreated, Chagas disease 

causes decreased life expectancy and 

can also result in death. 

The subject invention covers novel 

triazine and purine compounds that are 

inhibitors of key proteases (cruzain and 

Rhodesian) of the parasites 

Trypanosoma brucei rhodesiensi and 

Trypanosoma cruzi, respectively. 

Applications: Prophylactic and 

therapeutic treatment of African 

trypanosomiasis and Chagas disease. 

Advantages 

• Novel compounds against the 

cysteine proteases, cruzain and 

rhodesain. 

• Compounds possess low nanomolar 

inhibitory potential against cruzain and 

rhodesain. 

Development Status: In vitro and in 

vivo data are available upon request and 

upon execution of an appropriate 

confidentiality agreement. 

Inventors: Craig J. Thomas et al. 

(NHGRI). 

Related Publication: BT Mott et al. 

Identification and optimization of 

inhibitors of Trypanosomal cysteine 


emcdonald on DSK2BSOYB1PROD with NOTICES
81626 Federal Register / Vol. 75, No. 248 / Tuesday, December 28, 2010 / Notices 

proteases: cruzain, rhodesain, and 

TbCatB. J Med Chem. 2010 Jan 

14;53(1):52–60. [PubMed: 19908842] 

Patent Status: PCT Application No. 

PCT/US2009/063078 filed 03 Nov 2009, 

which published as WO 2010/059418 

on 27 May 2010 (HHS Reference No. E– 

267–2008/0–PCT–02) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIH Chemical Genomics Center 

(NCGC) is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize appropriate lead 

compounds described in the patent 

application. Please contact Dr. Craig J. 

Thomas (craigt@nhgri.nih.gov) or Claire 

Driscoll (cdriscol@mail.nih.gov), 

Director of the NHGRI Technology 

Transfer Office, for more information. 

A Novel, Inhibitory Platelet Surface 

Protein (TREM Like Transcript, TLT–1): 

New Target for the Treatment of 

Cancer, Infectious Diseases, Cardiac 

Diseases, and Platelet-Associated 

Disorders 

Description of Technology: Triggering 

Receptors in Myeloid Cells (TREM) 

recently were discovered to modulate 

innate and adaptive immunity. 

Specifically, TREM1 amplifies the 

response to sepsis in innate immunity 

by activating neutrophils and other 

leukocytes; and TREM2 potentiates 

dendritic cell maturation in adaptive 

immunity. 

This invention describes a novel, 

inhibitory platelet surface protein 

known as TREM like Transcript (TLT– 

1). TLT–1 is the first inhibitory receptor 

discovered to reside within the TREM 

gene locus. Structurally, TLT–1 also 

possesses inhibitory domains that 

indicate this regulatory function. TLT– 

1 is highly expressed in peripheral 

blood platelets and may modulate many 

other types of myeloid cells. 

Additionally, the invention describes 

specific, human, single chain antibodies 

(scFvs) that recognize TLT–1. 

Applications 

• This discovery implies the receptor 

has an important regulatory role in both 

innate and adaptive immunity. 

• TLT–1 is a potential therapeutic 

target for thrombosis and other plateletassociated disorders, as well as immune 

disorders, cancer, septic shock, 

infectious disease, stroke, heart disease, 

myocardial infarction, vascular 

disorders. 

• Detection of soluble TLT–1 in 

patient plasma suggests the protein is a 

marker of ongoing coagulopathies. 

• Defective platelet aggregation in 

TLT–1 null mice confirms a role for the 

protein in regulation of thrombosis 

associated with inflammation. 

Advantages 

• In vitro proof of concept data 

available—Three of the anti-TLT–1 

scFvs inhibit thrombin-induced 

aggregation of human platelets in a 

dose-dependent manner. 

• Complete human origin of these 

antibodies suggests negligible 

immunogenicity and minimizes the 

problem of adverse immune responses 

in human therapy. 

• Target validation is complete. TLT– 

1 null mice demonstrate defects in 

platelet aggregation with no gross 

bleeding defect. 

Development Status: In vitro 

experiments completed. Target 

validation with null mice completed. In 

vivo animal studies with scFv are 

currently ongoing. 

Inventors: Toshiyuki Mori et al. (NCI) 

Related Publication: Giomarelli B, 

Washington VA, Chisholm MM, Quigley 

L, McMahon JB, Mori T, McVicar DW. 

Inhibition of thrombin-induced platelet 

aggregation using human single-chain 

Fv antibodies specific for TREM-like 

transcript-1. Thromb Haemost. 2007 

Jun;97(6):955–963. [PubMed: 17549298] 

Patent Status: U.S. Patent No. 

7,553,936 issued on 30 Jun 2009 (HHS 

Reference No. E–177–2006/0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty B. Tong, 

PhD; 301–594–6565; 

tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute’s 

Molecular Targets Development 

Program is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize antibodies that react 

specifically with TLT–1. Please contact 

John D. Hewes, PhD at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: December 21, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–32629 Filed 12–27–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Engineered Biological Pacemakers 

Description of Technology: A common 

symptom of many heart diseases is an 

abnormal heart rhythm or arrhythmia. 

While effectively improving the lives of 

many patients, implantable pacemakers 

have significant limitations such as 

limited power sources, risk of 

infections, potential for interference 

from other devices, and absence of 

autonomic rate modulation. 

The technology consists of biological 

pacemakers engineered to generate 

normal heart rhythm. The biological 

pacemakers include cardiac cells or 

cardiac-like cells derived from 

embryonic stem cells or mesenchymal 

stem cells. The biological pacemakers 

naturally integrate into the heart. Their 

generation of rhythmic electric impulses 

involves coupling factors, such as 

cAMP-dependent PKA and Ca2+

-dependent CaMK II, which are 

regulatory proteins capable of 

modulating/enhancing interactions (i.e. 

coupling) of the sarcoplasmic reticulumbased, intracellular Ca2+ clock and the 

surface membrane voltage clock, thereby 

converting irregularly or rarely 

spontaneously active cells into 

pacemakers generating rhythmic 

excitations. 


emcdonald on DSK2BSOYB1PROD with NOTICES